Nephronophthisis 13
diseaseOn this page
Also known as nephronophthisis type 13NPHP13
Summary
Nephronophthisis 13 (MONDO:0013718) is a disease caused by WDR19 (GenCC Strong), with 1 cohort gene.
At a glance
- Causal gene: WDR19 (GenCC Strong)
- Cohort genes: 1
- ClinVar variants: 295
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | nephronophthisis 13 |
| Mondo ID | MONDO:0013718 |
| OMIM | 614377 |
| DOID | DOID:0111121 |
| UMLS | C3280612 |
| MedGen | 482242 |
| GARD | 0024942 |
| Is cancer (heuristic) | no |
Also known as: nephronophthisis 13 · nephronophthisis type 13 · NPHP13
Data availability: 295 ClinVar variants · 1 GenCC gene-disease record.
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal recessive disease › nephronophthisis › nephronophthisis 13
Related subtypes (17): nephronophthisis 1, nephronophthisis 2, nephronophthisis 3, nephronophthisis 4, nephronophthisis 7, nephronophthisis-like nephropathy 1, nephronophthisis 11, nephronophthisis 12, nephronophthisis 9, nephronophthisis 14, nephronophthisis 15, nephronophthisis 16, nephronophthisis 18, nephronophthisis 19, nephronophthisis 20, late-onset nephronophthisis, nephronophthisis-like nephropathy 2
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
295 retrieved; paginated sample, class counts are floors:
173 uncertain significance, 30 likely pathogenic, 25 likely benign, 20 pathogenic/likely pathogenic, 14 conflicting classifications of pathogenicity, 13 benign, 12 benign/likely benign, 8 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 1071987 | NM_025132.4(WDR19):c.1122_1123insT (p.Pro375fs) | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1179139 | NM_025132.4(WDR19):c.2601_2602dup (p.Tyr868fs) | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1213952 | NM_025132.4(WDR19):c.2485C>T (p.Arg829Ter) | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 127154 | NM_025132.4(WDR19):c.641dup (p.Leu214fs) | WDR19 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 127156 | NM_025132.4(WDR19):c.682C>T (p.Gln228Ter) | WDR19 | Pathogenic | no assertion criteria provided |
| 127157 | NM_025132.4(WDR19):c.3703G>A (p.Glu1235Lys) | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 127158 | NM_025132.4(WDR19):c.3533G>A (p.Arg1178Gln) | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 127159 | NM_025132.4(WDR19):c.3565+1G>A | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1382656 | NM_025132.4(WDR19):c.3319C>T (p.Gln1107Ter) | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1451170 | NM_025132.4(WDR19):c.441G>A (p.Trp147Ter) | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1473602 | NM_025132.4(WDR19):c.3184-2A>C | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1686922 | NM_025132.4(WDR19):c.1853T>C (p.Leu618Pro) | WDR19 | Pathogenic | no assertion criteria provided |
| 280765 | NM_025132.4(WDR19):c.2363+1G>A | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2925026 | NM_025132.4(WDR19):c.2138_2139del (p.Ile713fs) | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 30703 | NM_025132.4(WDR19):c.2129T>C (p.Leu710Ser) | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 30706 | NM_025132.4(WDR19):c.1034T>G (p.Val345Gly) | WDR19 | Pathogenic | no assertion criteria provided |
| 30707 | NM_025132.4(WDR19):c.3068dup (p.Tyr1023Ter) | WDR19 | Pathogenic | no assertion criteria provided |
| 3590548 | NM_025132.4(WDR19):c.2716del (p.Glu906fs) | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 446633 | NM_025132.4(WDR19):c.817A>G (p.Asn273Asp) | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 446634 | NM_025132.4(WDR19):c.781dup (p.Thr261fs) | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 446635 | NM_025132.4(WDR19):c.880G>A (p.Gly294Arg) | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 558759 | NM_025132.4(WDR19):c.1623C>G (p.Tyr541Ter) | WDR19 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 562401 | NM_025132.4(WDR19):c.14T>C (p.Phe5Ser) | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 568100 | NM_025132.4(WDR19):c.1982+2T>C | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 625691 | GRCh37/hg19 4p14(chr4:39215680-39219295) | WDR19 | Pathogenic | criteria provided, single submitter |
| 632439 | NM_025132.4(WDR19):c.641T>A (p.Leu214Ter) | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 802068 | NM_025132.4(WDR19):c.1250-1G>A | WDR19 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 974370 | NM_025132.4(WDR19):c.2333C>G (p.Ser778Ter) | WDR19 | Pathogenic | criteria provided, single submitter |
| 2627408 | NM_025132.4(WDR19):c.1015C>T (p.Gln339Ter) | WDR19 | Likely pathogenic | criteria provided, single submitter |
| 3236428 | NM_025132.4(WDR19):c.716+2T>C | WDR19 | Likely pathogenic | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 12 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| WDR19 | Strong | Autosomal recessive | nephronophthisis 13 | 12 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| WDR19 | Orphanet:1515 | Cranioectodermal dysplasia |
| WDR19 | Orphanet:3156 | Senior-Loken syndrome |
| WDR19 | Orphanet:474 | Jeune syndrome |
| WDR19 | Orphanet:93592 | Juvenile nephronophthisis |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| WDR19 | HGNC:18340 | ENSG00000157796 | Q8NEZ3 | WD repeat-containing protein 19 | gencc,clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| WDR19 | WD repeat-containing protein 19 | As component of the IFT complex A (IFT-A), a complex required for retrograde ciliary transport and entry into cilia of G protein-coupled receptors (GPCRs), it is involved in cilia function and/or assembly. |
Protein-family classification
Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Transcription factor | 1 | 8.3× | 0.121 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| WDR19 | Transcription factor | no | WD40_rpt, TPR-like_helical_dom_sf, WD40/YVTN_repeat-like_dom_sf |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| adenohypophysis | 1 |
| bronchial epithelial cell | 1 |
| right uterine tube | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| WDR19 | 269 | ubiquitous | marker | right uterine tube, bronchial epithelial cell, adenohypophysis |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| WDR19 | 1,251 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| WDR19 | Q8NEZ3 | 4 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 2. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Intraflagellar transport | 1 | 200.3× | 0.006 | WDR19 |
| Hedgehog ‘off’ state | 1 | 178.4× | 0.006 | WDR19 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| ear morphogenesis | 1 | 4213.0× | 9e-04 | WDR19 |
| smoothened signaling pathway involved in dorsal/ventral neural tube patterning | 1 | 4213.0× | 9e-04 | WDR19 |
| myotome development | 1 | 4213.0× | 9e-04 | WDR19 |
| digestive system development | 1 | 3370.4× | 9e-04 | WDR19 |
| protein localization to ciliary membrane | 1 | 3370.4× | 9e-04 | WDR19 |
| embryonic camera-type eye development | 1 | 1203.7× | 0.002 | WDR19 |
| nervous system process | 1 | 1203.7× | 0.002 | WDR19 |
| gonad development | 1 | 1123.5× | 0.002 | WDR19 |
| intraciliary retrograde transport | 1 | 1123.5× | 0.002 | WDR19 |
| receptor clustering | 1 | 624.1× | 0.003 | WDR19 |
| embryonic cranial skeleton morphogenesis | 1 | 581.1× | 0.003 | WDR19 |
| embryonic limb morphogenesis | 1 | 401.2× | 0.003 | WDR19 |
| cell morphogenesis | 1 | 157.5× | 0.008 | WDR19 |
| protein-containing complex assembly | 1 | 113.9× | 0.010 | WDR19 |
| cilium assembly | 1 | 73.6× | 0.014 | WDR19 |
| in utero embryonic development | 1 | 72.0× | 0.014 | WDR19 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| WDR19 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | WDR19 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| WDR19 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: WDR19